Nurix Therapeutics (NRIX) Net Income towards Common Stockholders (QoQ) (2019 - 2026)
Powered by 
Analysis
Nurix Therapeutics (NRIX) Net Income towards Common Stockholders (QoQ) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Nurix Therapeutics | 2.90 Bn | 2.46 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| May 31, 2026 | -2.71% |
| Feb 28, 2026 | -11.45% |
| Nov 30, 2025 | 9.49% |
| Aug 31, 2025 | -98.83% |
| May 31, 2025 | 22.87% |
| Feb 28, 2025 | 3.75% |
| Nov 30, 2024 | -19.60% |
| Aug 31, 2024 | -9.90% |
| May 31, 2024 | -7.29% |
| Feb 29, 2024 | 1.04% |
| Nov 30, 2023 | -13.45% |
| Aug 31, 2023 | -52.33% |
| May 31, 2023 | 40.40% |
| Feb 28, 2023 | 12.81% |
| Nov 30, 2022 | -2.21% |
| Aug 31, 2022 | -0.68% |
| May 31, 2022 | -6.74% |
| Feb 28, 2022 | -12.85% |
| Nov 30, 2021 | -30.71% |
| Aug 31, 2021 | -9.30% |